布-加综合征并发肝细胞癌多学科协作诊治专家共识(2023版)
Expert consensus on multidisciplinary collaborative diagnosis and treatment of Budd-Chiari syndrome complicated by hepatocellular carcinoma(2023 Edition)
中国研究型医院学会布-加综合征及肝脏血管病专业委员会 党晓卫1
作者信息
- 1. 郑州大学第一附属医院肝胆胰外科 河南省布-加综合征诊疗中心,郑州 450052
- 折叠
摘要
布-加综合征(B-CS)是肝脏血液流出道阻塞引起的复杂肝脏血管疾病,可导致淤血性肝纤维化、肝硬化.肝细胞癌(HCC)是B-CS的严重并发症,对患者生命危害极大.B-CS并发HCC病情复杂,其诊治与其他原因引起的HCC存在差异.为进一步规范和提高我国B-CS并发HCC的综合诊治水平,中国研究型医院学会布-加综合征及肝脏血管病专业委员会针对B-CS并发HCC的流行病学、临床表现、诊断与治疗、监测随访等问题,组织多学科专家,综合国内外该领域研究进展及临床实践,制定了《布-加综合征并发肝细胞癌多学科协作诊治专家共识(2023版)》,供临床参考.
Abstract
Budd-Chiari syndrome(B-CS)is a complex hepatic vascular disease caused by obstruction of hepatic venous outflow,which can lead to congestive liver fibrosis and cirrhosis.Hepatocellular carcinoma(HCC)is a severe complication of B-CS,posing a significant threat to patients'lives.The condition of B-CS complicated by HCC is intricate,with diagnosis and therapeutic differences from HCC caused by other factors.To further standardize and improve the comprehensive diagnosis and treatment of B-CS complicated by HCC in China,Budd-Chiari Syndrome and Hepatic Vascular Diseases Professional Committee of Chinese Research Hospital Association organized multidisciplinary experts to review domestic and international research progress and clinical practices in this field,leading to the formulation of the"Expert consensus on multidisciplinary collaborative diagnosis and treatment of Budd-Chiari syndrome complicated by hepatocellular carcinoma(2023 Edition)",which serves as a clinical reference.
关键词
Budd-Chiari综合征/癌,肝细胞/多学科诊疗/专家共识Key words
Budd-Chiari syndrome/Carcinoma,hepatocellular/Multidisciplinary diagnosis and treatment/Specialist consensus引用本文复制引用
出版年
2024
NETL
NSTL
万方数据